Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

92.33 +1.71 (+1.89%)

Streaming Delayed Price Updated: 10:26 AM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

26 27 Next >

Earnings Outlook For Incyte ↗

February 06, 2023

Via Benzinga

2 Steady Stocks to Buy in a Recession ↗

February 03, 2023

Both companies are performing better than the broader market over the past year.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗

January 31, 2023

Via Benzinga

Incyte to Present at Upcoming Investor Conference

January 24, 2023

From Incyte

Via Business Wire

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 19, 2023

On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.

Via Investor's Business Daily

Golden Cross Appears Before Incyte Investors ↗

December 09, 2022

Via Benzinga

Expert Ratings for Incyte ↗

October 18, 2022

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Via Benzinga

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers ↗

January 18, 2023

From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock...

Via Talk Markets

Incyte to Report Fourth Quarter and Year-End 2022 Financial Results

January 17, 2023

From Incyte

Via Business Wire

Why These 7 Healthcare Stocks Could Soar in 2023 ↗

January 02, 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Via InvestorPlace

Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion ↗

December 31, 2022

China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by...

Via Talk Markets

2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗

December 29, 2022

These two biotechs are flying high right now.

Via The Motley Fool

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗

December 18, 2022

These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.

Via InvestorPlace

Cramer Says He's 'Always Liked' This Drug Company ↗

December 16, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Oshkosh Corporation (NYSE: OSK) is a "slow grower.

Via Benzinga

Incyte to Present at Upcoming Investor Conferences

December 15, 2022

From Incyte

Via Business Wire

BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients ↗

December 13, 2022

Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX<

Via Benzinga

Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

December 11, 2022

From Incyte

Via Business Wire

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022

December 10, 2022

From Incyte

Via Business Wire

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

December 02, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

November 17, 2022

From Incyte

Via Business Wire

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

November 07, 2022

From Incyte and Mirati

Via Business Wire

Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

November 07, 2022

From Incyte

Via Business Wire

7 Cash-Rich Stocks to Buy for Peace of Mind ↗

November 04, 2022

It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.

Via InvestorPlace

2 Biotech Stocks That Could Make You Richer ↗

November 04, 2022

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Via The Motley Fool

More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting

November 03, 2022

From Incyte

Via Business Wire

Recap: Incyte Q3 Earnings ↗

November 01, 2022

Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by...

Via Benzinga

Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

November 01, 2022

From Incyte

Via Business Wire

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

October 19, 2022

From Incyte

Via Business Wire

Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' ↗

October 17, 2022

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.